Making cancer screening earlier,
more accurate, accessible and convenient.
LAMH is an Al-driven cancer screening and diagnostic innovation enter- prise, founded by international business leaders, top scientists and medical professionals, with the idea of "making cancer screening earlier, more accurate,more accessible and easierLAMH is the "Global first and only" early cancer screening and di- agnostic company that is fully established in China and the United States, the world's two largest economies, for technology de- velopment,manufacturing,NMPA/FDA approval and commercialization.On June 20.2023.Guangzhou Elitehealth Biotech Co.LTD.a GMP entity of LAMH, accomplished a remarkable milestone by obtaining the world's first (and currently the only)registration certificate for liver cancer early screening from the China National Medical Products Administration(NMPA).The Company successfully launched its liver cancer early screening products,甘倍康and HelioLiver in China and the U.S. respectivelyproviding accurate, accessible,and user-friendly screening and diagnostic solutions for liver cancer. This groundbreaking achievement has revolutionized the landscape of clinical screening, diagnosis, and monitoring of liver cancer, thereby establishing and enhancing the standards and protocols for cancer screening in both coun- tries. By adopting a value-based medicine approach, the company aims to address the challenges associated with early cancer screening,diagnosis, and treatment. effectively meeting the unmet clinical and health needs in both China and the United States.
The Chinese independent entity LAMH is headquartered in the Pazhou Central Business District, Guangzhou. It has a research and registration center in the Beijing Economic and Technological Development Zone, Southern and Northern medical testing labs (ICL) compliant with PCR and NGS standards in Guangzhou's Biotech Island and Beijing's Yizhuang respectively. A NMPA-assessed IVD GMP factory is located in Guangzhou's Science City. The American independent entity Helio Genomics is based in Irvine, California, with a certified CLIA and CAP central lab in Indiana.
Mission
Making cancer screening earlier,
more accurate, accessible and convenient.
Vision
A technology-driven global leader
in early cancer detection.
Values
Result-oriented, customer-centric,
and people-oriented.
Mr. Zeyue Zhang is the Chairman and CEO of LAMH, leading the company to obtain the world's first National Pharmacovigilance Certificate in the field of early liver cancer screening, and becoming the only company to obtain full reimbursement code and pricing from US commercial insurance. Dedicated to the cause of cancer prevention and treatment, he has worked in well-known domestic gene companies such as BGI and CapitalBio MedLab, as well as global pharmaceutical companies such as Eli Lilly, Roche, and Novartis, and also has experience in management of start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He is a recipient of the《Fortune》‘40 under 40 Business Leader’.
Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.
Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.